Outcomes of haploidentical stem cell transplan... - CLL Support

CLL Support

22,367 members38,474 posts

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study

Cllcanada profile image
CllcanadaTop Poster CURE Hero
1 Reply

An allogeneic haemopoietic stem cell (HPC) transplant involves matching a patient’s tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related or unrelated donor. HLA proteins are found on all cells of our body and are the main way the immune system tells the difference between our own cells and foreign cells.

The closer the HLA match between a donor and recipient, the greater the chance a transplant will be successful.

If the HLA match is not close enough, the donor’s immune system, which accompanies the donated stem cells, recognises the HLA mismatch, and will attack the recipient’s tissues. This process is known as graft versus host disease (GVHD).

...

Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL).

Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively.

All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

Paywalled

nature.com/articles/s41409-...

Written by
Cllcanada profile image
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...
1 Reply
Wroxham profile image
Wroxham

Superb photo Chris.

You may also like...

Still on hold for stem cell transplant

results were good, that his cancer cells had been reduced sufficiently to proceed with transplant....

10 months post Stem Cell Transplant

months ago I was lucky enough to receive donor cells from a 10/10 match. It's been a rollercoaster...

Stem cell transplant

mentioned that they would take tissue for an allogenic stem cell transplant as a plan B if the...

Chronic lymphocytic leukemia

needle biopsy I was diagnosed with low grade B cell lymphoma. Oncologist wanted an excisional...

Information on chronic lymphocytic leukemia